| Identification | Back Directory | [Name]
para-Hydroxy Atorvastatin CalciuM Salt | [CAS]
265989-44-4 | [Synonyms]
4-Hydroxy Atorvastatin
Atorvastatin Impurity J
Atorvastatin Impurity 52
Atorvastatin Impurity 154
Para-Hydroxy Atorvastatin Calcium
4-Hydroxy Atorvastatin HeMicalciuM Salt
calcium,(3S,5S)-7-[2-(4-fluorophenyl)-4-[(4-hydroxyphenyl)carbamoyl]-3-phenyl-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate
Atorvastatin impurity 35/para-Hydroxy Atorvastatin Calcium Salt/(3R,5R)-7-[2-(4-fluorophenyl)-4-[(4-hydroxyphenyl)carbamoyl]-3-phenyl-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate Calcium Salt
4-Hydroxy-Atorvastatin calcium saltQ: What is
4-Hydroxy-Atorvastatin calcium salt Q: What is the CAS Number of
4-Hydroxy-Atorvastatin calcium salt Q: What is the storage condition of
4-Hydroxy-Atorvastatin calcium salt Q: What are the applications of
4-Hydroxy-Atorvastatin calcium salt | [Molecular Formula]
C66H70CaF2N4O12 | [MOL File]
265989-44-4.mol | [Molecular Weight]
1189.36 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 25 mg/ml; DMF:PBS (pH 7.2) (1:9): 0.1 mg/ml; DMSO: 15 mg/ml; Ethanol: 0.5 mg/ml | [form ]
A crystalline solid | [InChIKey]
ANSBACJULZIWOU-DJNTWTPDSA-N |
| Hazard Information | Back Directory | [Description]
4-hydroxy Atorvastatin is a metabolite of atorvastatin , an HMG-CoA reductase inhibitor present in formulations that have been used to treat hypercholesterolemia and certain dyslipidemias.1,2,3,4 Atorvastatin is metabolized by the cytochrome P450 (CYP) isoform CYP3A4 to form 4-hydroxy atorvastatin.1 | [References]
1. Hong, J.H., Youm, J.K., Kwon, M.J., et al. K6PC-5, a direct activator of sphingosine kinase 1, promotes epidermal differentiation through intracellular Ca2+ signaling J. Invest. Dermatol. 128,2166-2178(2008).
2. Dart, A., Jerums, G., Nicholson, G., et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia Am. J. Cardiol. 80(1),39-44(1997).
3. Group, T.D.A.L.I.S. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. The DALI study: A double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia Diabetes Care 24(8),1335-1341(2001).
4. van Dam, M., Zwart, M., de Beer, F., et al. Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia Heart 88(3),234-238(2002). |
|
| Company Name: |
OPULENT PHARMA
|
| Tel: |
+91-9106692785 |
| Website: |
www.www.NOWEBSITE |
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|